ArticleJournal of the American Society of Nephrology : JASN2010
Subclinical viremia increases risk for chronic allograft injury in pediatric renal transplantation.
Article in Journal of the American Society of Nephrology : JASN, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 108 citations in OpenAlex.
- Less renal allograft fibrosis with valganciclovir prophylaxis for cytomegalovirus compared to high-dose valacyclovir: a parallel group, open-label, randomized controlled trial.BMC infectious diseases · 2018Trial
- Randomized trial of valganciclovir versus valacyclovir prophylaxis for prevention of cytomegalovirus in renal transplantation.Clinical journal of the American Society of Nephrology : CJASN · 2015Trial
- Long-term outcomes of pre-emptive valganciclovir compared with valacyclovir prophylaxis for prevention of cytomegalovirus in renal transplantation.Journal of the American Society of Nephrology : JASN · 2012Trial
- Debates in Management and Treatment of CMV in Pediatric Solid Organ Transplant Recipients: A Case-Based Discussion.Pediatric transplantation · 2025Review
- Acute kidney injury in paediatric kidney transplant recipients.Pediatric nephrology (Berlin, Germany) · 2025Review
- Valacyclovir versus valganciclovir for cytomegalovirus prophylaxis in kidney transplant recipients: a systematic review and comparative meta-analysis.Clinical transplantation and research · 2025Article
- Incidence, risk factors, management strategies, and outcomes of antibody-mediated rejection in pediatric kidney transplant recipients-a multicenter analysis of the Cooperative European Paediatric Renal Transplant Initiative (CERTAIN).Pediatric nephrology (Berlin, Germany) · 2025Article
- Association of Cytomegalovirus (CMV) DNAemia With Long-Term Mortality in a Randomized Trial of Preemptive Therapy and Antiviral Prophylaxis for Prevention of CMV Disease in High-Risk Donor Seropositive, Recipient Seronegative Liver Transplant Recipients.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2024Article
- Valganciclovir is not associated with decreased EBV infection rate in pediatric kidney transplantation.Frontiers in pediatrics · 2022Article
- Incidence of Cytomegalovirus DNAemia in Pediatric Post-Renal Transplant Patients Receiving Weight-Based vs Body Surface Area-Based Valganciclovir Chemoprophylaxis.The journal of pediatric pharmacology and therapeutics : JPPT : the official journal of PPAG · 2022Article
- National survey of prevention and management of CMV infection in pediatric kidney transplantation in comparison to clinical practice guidelines.Frontiers in pediatrics · 2022Article
- Early renal function trajectories, cytomegalovirus serostatus and long-term graft outcomes in kidney transplant recipients.BMC nephrology · 2021Article
- Valganciclovir prophylaxis delays onset of EBV viremia in high-risk pediatric solid organ transplant recipients.Pediatric research · 2020Article
- Long-lasting chronic high load carriage of Epstein-Barr virus is more common in young pediatric renal transplant recipients.Pediatric nephrology (Berlin, Germany) · 2020Article
- The Humoral Immune Response Against the gB Vaccine: Lessons Learnt from Protection in Solid Organ Transplantation.Vaccines · 2019Review
- Cytomegalovirus and Epstein-Barr virus infections among pediatric kidney transplant recipients at a center using universal Valganciclovir Prophylaxis.Pediatric transplantation · 2019Article
- Prospective Assessment of Adenovirus Infection in Pediatric Kidney Transplant Recipients.Transplantation · 2018Article
- Cytomegalovirus Infection under a Hybrid Strategy in Pediatric Liver Transplantation: A Single-Center Experience.Pediatric gastroenterology, hepatology & nutrition · 2017Article
- Infection rates in tacrolimus versus cyclosporine-treated pediatric kidney transplant recipients on a rapid discontinuation of prednisone protocol: 1-year analysis.Pediatric transplantation · 2017Article
- Relationship Among Viremia/Viral Infection, Alloimmunity, and Nutritional Parameters in the First Year After Pediatric Kidney Transplantation.American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons · 2017Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 4 institutions in 1 country.
Funding
Abstract
The impact of subclinical viral infection on chronic allograft injury in the pediatric renal transplant population is not well defined. We prospectively assessed cytomegalovirus (CMV) and Epstein-Barr virus (EBV) DNAemia by monthly PCR in 55 pediatric renal transplant recipients for the first 2 years after transplantation. Subclinical CMV and EBV infection occurred in 22 and 36%, respectively. Multivariable linear regression analysis suggested that both subclinical CMV and EBV infection independently associate with significant declines in GFR during the first 2 years after transplantation. CMV seronegativity associated with a significantly greater decline in GFR than seropositivity (P < 0.01). Subclinical CMV infection and subclinical EBV infection each associated with approximately fourfold greater odds of histologic evidence of chronic allograft injury (odds ratio 4.61 [95% confidence interval 1.18 to 18.07] and odds ratio 4.33 [95% confidence interval 1.34 to 14.00], respectively). An increase in viral load of CMV or EBV also associated with increased risk for moderate to severe chronic allograft injury. Taken together, these results demonstrate an association between subclinical CMV and EBV infections, which occur despite standard antiviral prophylaxis, and chronic allograft injury in pediatric renal transplant recipients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.